Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 30 versus FML S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 30 versus FML S.
BLEPH-30 vs FML-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLEPH-30 is a topical formulation containing 30% sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, interfering with folic acid synthesis and exerting bacteriostatic activity against susceptible organisms.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production. This results in decreased inflammation, edema, and immune cell infiltration. Sulfacetamide is a sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking folate synthesis and bacterial growth.
One drop to the affected eye(s) every 12 hours. Not to exceed 2 drops per eye per day.
1-2 drops of 0.1% ophthalmic suspension into the conjunctival sac every 4 hours; may increase to every 2 hours in severe inflammation.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours in adults with normal renal function; clinically, dosing intervals may need adjustment in renal impairment.
2.8-3.5 hours; prolonged to 8-12 hours in renal impairment or in neonates
Primarily renal excretion of unchanged drug, accounting for approximately 90% of elimination; minor biliary/fecal route (<10%).
Renal (65-75% as unchanged drug and metabolites), biliary/fecal (15-25%)
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination